Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

6.140 -0.160 (-2.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine Mindmed Inc

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
31 32 Next >
Transcript: Jason Raznick's Conversation with Mr. Wonderful Kevin O'Leary At The Benzinga Psychedelics Conference
On this special edition of the RazReport, Benzinga Founder & CEO Jason Raznick sits down with Kevin O'Leary AKA Mr. Wonderful at the Benzinga Psychedelics Capital... 
Via Benzinga
Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 3.67% at $0.57 LOSERS: 
Via Benzinga
Landmark Gathering Of Psychedelics Executives And Scientists To Take Place In London May 11
As the field of psychedelic medicine moves forward and international borders begin to open up, an expanding offering of conferences and live events are becoming available for investors, industry people... 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 28, 2022
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 4.35% at $1.20 
Via Benzinga
Oregon to Become the First State to Legally Roll Out Psilocybin
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in... 
Via FinancialNewsMedia
Topics Derivatives ETFs
Exposures Derivatives
Psychedelic Stock Gainers And Losers From April 27, 2022
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 3.77% at $0.28 
Via Benzinga
EXCLUSIVE: Lessons Learned At The Benzinga 2022 Psychedelics And Cannabis Capital Conferences
Benzinga, a large content provider to brokerages and news outlets, hosts live conferences to recognize disruptive innovation in finance and technology, trading, and emerging... 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.61% at $0.29 
Via Benzinga
Pro-Patient Psychedelic Treatments Are Finally Moving Forward In A 'New Paradigm Shift'
Last week, Benzinga’s Psychedelics Capital Conference brought a premier gathering of the biggest publicly traded psychedelics companies in North America with forward-thinking investors to Miami, where... 
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97 
Via Benzinga
Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87 
Via Benzinga
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 20.83% at $0.29 
Via Benzinga
Why MindMed’s LSD Trial for Anxiety May Be Important to Psychedelic Investors
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From April 20, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.69% at $0.16 LOSERS: 
Via Benzinga
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.57% at $0.33 
Via Benzinga
EXCLUSIVE: Breaking Down Public Vs. Private Psychedelic Investments
For many private companies, the goal is clear: to go public. For others, the goal is an acquisition. Either way, private companies offer attractive potential for investors, especially in emerging... 
Via Benzinga
EXCLUSIVE: Why Kevin O'Leary Of 'Shark Tank' Says Public Psychedelics Companies Will Need To Merge
The market opportunity for legal psychedelics is in the hundreds of billions of dollars, “Shark Tank” judge Kevin O’Leary told the inaugural Benzinga Psychedelics Capital Conference on Tuesday. 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.66% at $0.28 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 14, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.41% at $0.24 
Via Benzinga
Numinus Wellness Strives To Become Psychedelic Research Hub After Acquisition Of Novamind Inc.
In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc. (OTC: NUMIF) is among the first to take action. 
Via Benzinga
Why Psychedelics Could Soon Replace Antidepressants
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults... 
Via FinancialNewsMedia
Psychedelic Stock Gainers And Losers From April 11, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.52% at $0.17 
Via Benzinga
Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.54% at $0.16 
Via Benzinga
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.48% at $0.14 
Via Benzinga
Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 4.78% at $19.73 LOSERS: 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 5, 2022
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 1.60% at $1.27 LOSERS: 
Via Benzinga
MindMed Appoints Francois Lilienthal As New CCO
With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. ... 
Via Benzinga
From Pharma To Psychedelics, Robert Barrow, CEO Of MindMed: Meet Our Speakers
With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ: MNMD) is someone ... 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.